Wyrsch, S; Thiel, M A; Becht, C N (2009). [Safety of treatment with tacrolimus ointment for anterior segment inflammatory diseases]. Klinische Monatsblätter für Augenheilkunde, 226(4), pp. 234-6. Stuttgart: Ferdinand Enke Verlag 10.1055/s-0028-1109328
Full text not available from this repository.BACKGROUND: The off-label use of topical tacrolimus (Protopic) for inflammatory external eye diseases is gaining popularity. However, there are no reports on the safety profile of this new treatment option. PATIENTS AND METHODS: We treated six patients with different inflammatory eye diseases with topical tacrolimus (Protopic 0.03 %) as off-label use in addition to the conventional anti-inflammatory treatment. Patients were interviewed for side effects and serum drug concentrations were measured under steady state conditions one hour after topical application of tacrolimus ointment. RESULTS: Two patients reported a slight burning sensation immediately after application, in one patient we found a slight worsening of the dry eye problems. No patient abandoned the treatment due to side effects. Serum drug concentrations remained below the analytical threshold in all cases (< 1.5 ng/ml). CONCLUSIONS: Tacrolimus for the topical treatment of anterior segment inflammatory eye diseases is well tolerated without detectable systemic drug resorption.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology |
UniBE Contributor: |
Wyrsch, Stefan |
ISSN: |
0023-2165 |
ISBN: |
19384773 |
Publisher: |
Ferdinand Enke Verlag |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 15:05 |
Last Modified: |
05 Dec 2022 14:20 |
Publisher DOI: |
10.1055/s-0028-1109328 |
PubMed ID: |
19384773 |
Web of Science ID: |
000265747900006 |
URI: |
https://boris.unibe.ch/id/eprint/28270 (FactScience: 119069) |
Actions (login required)
 |
Edit item |